Table of Contents
Advances in Hepatology
Volume 2014, Article ID 357965, 7 pages
http://dx.doi.org/10.1155/2014/357965
Review Article

Concepts and Treatment Approaches in Nonalcoholic Fatty Liver Disease

Division of Gastroenterology and Hepatology, Department of Medicine, Thomas Jefferson University Hospital, 132 South 10th Street, Philadelphia, PA 19107, USA

Received 20 August 2014; Accepted 14 November 2014; Published 30 November 2014

Academic Editor: Junyong Park

Copyright © 2014 Dina L. Halegoua-De Marzio and Jonathan M. Fenkel. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Caldwell and C. Argo, “The natural history of non-alcoholic fatty liver disease,” Digestive Diseases, vol. 28, no. 1, pp. 162–168, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. G. Bedogni, L. Miglioli, F. Masutti, C. Tiribelli, G. Marchesini, and S. Bellentani, “Prevalence of and risk factors for nonalcoholic fatty liver disease: the dionysos nutrition and liver study,” Hepatology, vol. 42, no. 1, pp. 44–52, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. C. P. de Oliveira, E. S. de Mello, V. A. F. Alves, S. M. Saviero, and E. Strauss, “Changes in histological criteria lead to different prevalences of nonalcoholic steatohepatitis in severe obesity,” Annals of Hepatology, vol. 6, no. 4, pp. 255–261, 2007. View at Google Scholar · View at Scopus
  4. C. Boza, A. Riquelme, L. Ibañez et al., “Predictors of nonalcoholic steatohepatitis (NASH) in obese patients undergoing gastric bypass,” Obesity Surgery, vol. 15, no. 8, pp. 1148–1153, 2005. View at Publisher · View at Google Scholar · View at Scopus
  5. F. Harnois, S. Msika, J.-M. Sabaté et al., “Prevalence and predictive factors of non-alcoholic steatohepatitis (NASH) in morbidly obese patients undergoing bariatric surgery,” Obesity Surgery, vol. 16, no. 2, pp. 183–188, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. K. J. P. Schwenger and J. P. Allard, “Clinical approaches to non-alcoholic fatty liver disease,” World Journal of Gastroenterology, vol. 20, no. 7, pp. 1712–1723, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. C. A. Matteoni, Z. M. Younossi, T. Gramlich, N. Boparai, and A. J. McCullough, “Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity,” Gastroenterology, vol. 116, no. 6, pp. 1413–1419, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. D. Kim, W. R. Kim, H. J. Kim, and T. M. Therneau, “Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States,” Hepatology, vol. 57, no. 4, pp. 1357–1365, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. M. J. Armstrong, L. A. Adams, A. Canbay, and W.-K. Syn, “Extrahepatic complications of nonalcoholic fatty liver disease,” Hepatology, vol. 59, no. 3, pp. 1174–1197, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. J. A. Marrero, R. J. Fontana, G. L. Su, H. S. Conjeevaram, D. M. Emick, and A. S. Lok, “NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States,” Hepatology, vol. 36, no. 6, pp. 1349–1354, 2002. View at Publisher · View at Google Scholar · View at Scopus
  11. C. P. Day and O. F. W. James, “Steatohepatitis: a tale of two 'Hits'?” Gastroenterology, vol. 114, no. 4, pp. 842–845, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Bugianesi, G. Marchesini, E. Gentilcore et al., “Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis,” Hepatology, vol. 44, no. 6, pp. 1648–1655, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. A. E. Feldstein, N. W. Werneburg, A. Canbay et al., “Free fatty acids promote hepatic lipotoxicity by stimulating TNF-α expression via a lysosomal pathway,” Hepatology, vol. 40, no. 1, pp. 185–194, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Yamaguchi, L. Yang, S. McCall et al., “Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis,” Hepatology, vol. 45, no. 6, pp. 1366–1374, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Jou, S. S. Choi, and A. M. Diehl, “Mechanisms of disease progression in nonalcoholic fatty liver disease,” Seminars in Liver Disease, vol. 28, no. 4, pp. 370–379, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Mouzaki, E. M. Comelli, B. M. Arendt et al., “Intestinal microbiota in patients with nonalcoholic fatty liver disease,” Hepatology, vol. 58, no. 1, pp. 120–127, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. M. D. Spencer, T. J. Hamp, R. W. Reid, L. M. Fischer, S. H. Zeisel, and A. A. Fodor, “Association between composition of the human gastrointestinal microbiome and development of fatty liver with choline deficiency,” Gastroenterology, vol. 140, no. 3, pp. 976–986, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. J. K. Dowman, J. W. Tomlinson, and P. N. Newsome, “Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis,” Alimentary Pharmacology & Therapeutics, vol. 33, no. 5, pp. 525–540, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. A. E. Feldstein, A. Wieckowska, A. R. Lopez, Y.-C. Liu, N. N. Zein, and A. J. McCullough, “Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study,” Hepatology, vol. 50, no. 4, pp. 1072–1078, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. V. Ratziu, J. Massard, F. Charlotte et al., “Diagnostic value of biochemical markers (Fibro Test-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fatty liver disease,” BMC Gastroenterology, vol. 6, article 6, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. I. N. Guha, J. Parkes, P. Roderick et al., “Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: validating the European liver fibrosis panel and exploring simple markers,” Hepatology, vol. 47, no. 2, pp. 455–460, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Yoneda, M. Yoneda, H. Mawatari et al., “Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD),” Digestive and Liver Disease, vol. 40, no. 5, pp. 371–378, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Ziol, A. Handra-Luca, A. Kettaneh et al., “Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C,” Hepatology, vol. 41, no. 1, pp. 48–54, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. M. Yoneda, K. Fujita, M. Inamori, A. Nakajima, M. Tamano, and H. Hiraishi, “Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD),” Gut, vol. 56, no. 9, pp. 1330–1331, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. R. P. Myers, G. Pomier-Layrargues, R. Kirsch et al., “Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients,” Hepatology, vol. 55, no. 1, pp. 199–208, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. V. De Lédinghen, V. W.-S. Wong, J. Vergniol et al., “Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan,” Journal of Hepatology, vol. 56, no. 4, pp. 833–839, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. K. Mariappan, K. J. Glaser, and R. L. Ehman, “Magnetic resonance elastography: a review,” Clinical Anatomy, vol. 23, no. 5, pp. 497–511, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Chen, J. A. Talwalkar, M. Yin, K. J. Glaser, S. O. Sanderson, and R. L. Ehman, “Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography,” Radiology, vol. 259, no. 3, pp. 749–756, 2011. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Yin, J. A. Talwalkar, K. J. Glaser et al., “Assessment of hepatic fibrosis with magnetic resonance elastography,” Clinical Gastroenterology and Hepatology, vol. 5, no. 10, pp. 1207–1213, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Huwart, C. Sempoux, E. Vicaut et al., “Magnetic resonance elastography for the noninvasive staging of liver fibrosis,” Gastroenterology, vol. 135, no. 1, pp. 32–40, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. G. A. Grandison and P. Angulo, “Can NASH be diagnosed, graded, and staged noninvasively?” Clinics in Liver Disease, vol. 16, no. 3, pp. 567–585, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. Z. M. Younossi, M. Stepanova, N. Rafiq et al., “Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality,” Hepatology, vol. 53, no. 6, pp. 1874–1882, 2011. View at Publisher · View at Google Scholar · View at Scopus
  33. A. J. Sanyal, C. Banas, C. Sargeant et al., “Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C,” Hepatology, vol. 43, no. 4, pp. 682–689, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. N. Bhala, P. Angulo, D. van der Poorten et al., “The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study,” Hepatology, vol. 54, no. 4, pp. 1208–1216, 2011. View at Publisher · View at Google Scholar · View at Scopus
  35. V. W.-S. Wong, R. S.-M. Chan, G. L.-H. Wong et al., “Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial,” Journal of Hepatology, vol. 59, no. 3, pp. 536–542, 2013. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Centis, R. Marzocchi, S. Di Domizio, M. F. Ciaravella, and G. Marchesini, “The effect of lifestyle changes in non-alcoholic fatty liver disease,” Digestive Diseases, vol. 28, no. 1, pp. 267–273, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. B. H. Goodpaster, J. P. DeLany, A. D. Otto et al., “Effects of diet and physical activity interventions on weight loss and cardiometabolic risk factors in severely obese adults: a randomized trial,” The Journal of the American Medical Association, vol. 304, no. 16, pp. 1795–1802, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. C. E. Fealy, J. M. Haus, T. P. J. Solomon et al., “Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease,” Journal of Applied Physiology, vol. 113, no. 1, pp. 1–6, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. P. Koh-Banerjee, N.-F. Chu, D. Spiegelman et al., “Prospective study of the association of changes in dietary intake, physical activity, alcohol consumption, and smoking with 9-y gain in waist circumference among 16 587 US men,” The American Journal of Clinical Nutrition, vol. 78, no. 4, pp. 719–727, 2003. View at Google Scholar · View at Scopus
  40. B. A. Neuschwander-Tetri, D. A. Ford, S. Acharya et al., “Dietary trans-fatty acid induced NASH is normalized following loss of trans-fatty acids from hepatic lipid pools,” Lipids, vol. 47, no. 10, pp. 941–950, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. H. P. Cotrim and C. Daltro, “Liver: does bariatric surgery reduce the severity of NAFLD?” Nature Reviews Gastroenterology and Hepatology, vol. 7, no. 1, pp. 11–13, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. A. R. Moschen, C. Molnar, A. M. Wolf et al., “Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression,” Journal of Hepatology, vol. 51, no. 4, pp. 765–777, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. C. K. Furuya Jr., C. P. M. S. de Oliveira, E. S. de Mello et al., “Effects of bariatric surgery on nonalcoholic fatty liver disease: preliminary findings after 2 years,” Journal of Gastroenterology and Hepatology, vol. 22, no. 4, pp. 510–514, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. N. C. Chavez-Tapia, F. I. Tellez-Avila, T. Barrientos-Gutierrez, N. Mendez-Sanchez, J. Lizardi-Cervera, and M. Uribe, “Bariatric surgery for non-alcoholic steatohepatitis in obese patients,” Cochrane Database Systematic Reviews, vol. 1, Article ID CD007340, 2010. View at Google Scholar · View at Scopus
  45. G. Zhou, R. Myers, Y. Li et al., “Role of AMP-activated protein kinase in mechanism of metformin action,” Journal of Clinical Investigation, vol. 108, no. 8, pp. 1167–1174, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. A. Mazza, B. Fruci, G. A. Garinis, S. Giuliano, R. Malaguarnera, and A. Belfiore, “The role of metformin in the management of NAFLD,” Experimental Diabetes Research, vol. 2012, Article ID 716404, 13 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  47. S. Nair, A. M. Diehl, M. Wiseman, G. H. Farr Jr., and R. P. Perrillo, “Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial,” Alimentary Pharmacology and Therapeutics, vol. 20, no. 1, pp. 23–28, 2004. View at Publisher · View at Google Scholar · View at Scopus
  48. V. Nobili, M. Manco, P. Ciampalini et al., “Metformin use in children with nonalcoholic fatty liver disease: an open-label, 24-month, observational pilot study,” Clinical Therapeutics, vol. 30, no. 6, pp. 1168–1176, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. J. W. Haukeland, Z. Konopski, H. B. Eggesbø et al., “Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial,” Scandinavian Journal of Gastroenterology, vol. 44, no. 7, pp. 853–860, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. M. K. Oh, J. Winn, and F. Poordad, “Review article: diagnosis and treatment of non-alcoholic fatty liver disease,” Alimentary Pharmacology & Therapeutics, vol. 28, no. 5, pp. 503–522, 2008. View at Publisher · View at Google Scholar · View at Scopus
  51. L. B. van Wagner and M. E. Rinella, “The role of insulin-sensitizing agents in the treatment of nonalcoholic steatohepatitis,” Therapeutic Advances in Gastroenterology, vol. 4, no. 4, pp. 249–263, 2011. View at Publisher · View at Google Scholar · View at Scopus
  52. S. H. Caldwell, C. K. Argo, and A. M. S. Al-Osaimi, “Therapy of NAFLD: insulin sensitizing agents,” Journal of Clinical Gastroenterology, vol. 40, supplement 1, pp. S61–S66, 2006. View at Google Scholar · View at Scopus
  53. R. Belfort, S. A. Harrison, K. Brown et al., “A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis,” The New England Journal of Medicine, vol. 355, no. 22, pp. 2297–2307, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. G. Lutchman, A. Modi, D. E. Kleiner et al., “The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis,” Hepatology, vol. 46, no. 2, pp. 424–429, 2007. View at Publisher · View at Google Scholar · View at Scopus
  55. G. P. Aithal, J. A. Thomas, P. V. Kaye et al., “Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis,” Gastroenterology, vol. 135, no. 4, pp. 1176–1184, 2008. View at Publisher · View at Google Scholar · View at Scopus
  56. A. J. Sanyal, N. Chalasani, K. V. Kowdley et al., “Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis,” The New England Journal of Medicine, vol. 362, no. 18, pp. 1675–1685, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. S. A. Harrison, S. Torgerson, P. Hayashi, J. Ward, and S. Schenker, “Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis,” American Journal of Gastroenterology, vol. 98, no. 11, pp. 2485–2490, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. E. R. Miller, R. Pastor-Barriuso, D. Dalal, R. A. Riemersma, L. J. Appel, and E. Guallar, “Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality,” Annals of Internal Medicine, vol. 142, no. 1, 2005. View at Google Scholar · View at Scopus
  59. N. Alkhouri, C. Carter-Kent, and A. E. Feldstein, “Apoptosis in nonalcoholic fatty liver disease: diagnostic and therapeutic implications,” Expert Review of Gastroenterology and Hepatology, vol. 5, no. 2, pp. 201–212, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. M. L. Shiffman, P. Pockros, J. G. McHutchison, E. R. Schiff, M. Morris, and G. Burgess, “Clinical trial: the efficacy and safety of oral PF-03491390, a pancaspase inhibitor—a randomized placebo-controlled study in patients with chronic hepatitis C,” Alimentary Pharmacology & Therapeutics, vol. 31, no. 9, pp. 969–978, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. V. Ratziu, M. Y. Sheikh, A. J. Sanyal et al., “A phase 2, randomized, double-blind, placebo-controlled study of GS-9450 in subjects with nonalcoholic steatohepatitis,” Hepatology, vol. 55, no. 2, pp. 419–428, 2012. View at Publisher · View at Google Scholar · View at Scopus
  62. M. Olaywi, T. Bhatia, S. Anand, and S. Singhal, “Novel anti-diabetic agents in non-alcoholic fatty liver disease: a mini-review,” Hepatobiliary and Pancreatic Diseases International, vol. 12, no. 6, pp. 584–588, 2013. View at Publisher · View at Google Scholar · View at Scopus
  63. J. E. Mells, P. P. Fu, S. Sharma et al., “Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a western diet,” The American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 302, no. 2, pp. G225–G235, 2012. View at Publisher · View at Google Scholar · View at Scopus
  64. J. L. Trevaskis, P. S. Griffin, C. Wittmer et al., “Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice,” American Journal of Physiology: Gastrointestinal and Liver Physiology, vol. 302, no. 8, pp. G762–G772, 2012. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Sharma, J. E. Mells, P. P. Fu, N. K. Saxena, and F. A. Anania, “GLP-1 analogs reduce hepatocyte steatosis and improve survival by enhancing the unfolded protein response and promoting macroautophagy,” PLoS ONE, vol. 6, no. 9, Article ID e25269, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. A. F. Hofmann, “Bile acids: trying to understand their chemistry and biology with the hope of helping patients,” Hepatology, vol. 49, no. 5, pp. 1403–1418, 2009. View at Publisher · View at Google Scholar · View at Scopus
  67. P. Lefebvre, B. Cariou, F. Lien, F. Kuipers, and B. Staels, “Role of bile acids and bile acid receptors in metabolic regulation,” Physiological Reviews, vol. 89, no. 1, pp. 147–191, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. C. Thomas, R. Pellicciari, M. Pruzanski, J. Auwerx, and K. Schoonjans, “Targeting bile-acid signalling for metabolic diseases,” Nature Reviews Drug Discovery, vol. 7, no. 8, pp. 678–693, 2008. View at Publisher · View at Google Scholar · View at Scopus
  69. D. A. A. Hollman, A. Milona, K. J. van Erpecum, and S. W. C. van Mil, “Anti-inflammatory and metabolic actions of FXR: insights into molecular mechanisms,” Biochimica et Biophysica Acta: Molecular and Cell Biology of Lipids, vol. 1821, no. 11, pp. 1443–1452, 2012. View at Publisher · View at Google Scholar · View at Scopus
  70. L. Adorini, M. Pruzanski, and D. Shapiro, “Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis,” Drug Discovery Today, vol. 17, no. 17-18, pp. 988–997, 2012. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Mudaliar, R. R. Henry, A. J. Sanyal et al., “Efficacy and safety of the farnesoid x receptor agonist Obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease,” Gastroenterology, vol. 145, no. 3, pp. 574–582, 2013. View at Publisher · View at Google Scholar · View at Scopus
  72. V. W. Wong, G. L. Wong, A. M. Chim et al., “Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study,” Annals of Hepatology, vol. 12, no. 2, pp. 256–262, 2013. View at Google Scholar · View at Scopus
  73. A. Vrieze, E. van Nood, F. Holleman F et al., “Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome,” Gastroenterology, vol. 143, no. 4, pp. 913.e7–916.e7, 2012. View at Publisher · View at Google Scholar
  74. J. A. Parnell, M. Raman, K. P. Rioux, and R. A. Reimer, “The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance,” Liver International, vol. 32, no. 5, pp. 701–711, 2012. View at Publisher · View at Google Scholar · View at Scopus